The Impact of Immunotherapy Use in Stage IIIA (T1-2N2) NSCLC: A Nationwide Analysis

CONCLUSIONS: Increased use of IO was associated with a change in treatment patterns and improved survival for patients with stage IIIA(N2) NSCLC.PMID:38496376 | PMC:PMC10941003 | DOI:10.1016/j.jtocrr.2024.100654

Source: Clinical Lung Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Lye-Yeng Wong Douglas Z Liou Mohana Roy Irmina A Elliott Leah M Backhus Natalie S Lui Joseph B Shrager Mark F Berry Source Type: research